Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia

Akira Manki, Toshiro Ono, Akiko Uenaka, Yoshiki Seino, Eiichi Nakayama

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

pRL1a (IPGLPLSL) is the L(d)-binding tumor rejection antigen peptide recognized by CTLs on BALB/c radiation leukemia RL♂1. We demonstrated that in vivo and in vitro sensitization with pRL1a multiple antigen peptide (MAP), but not with the pRL1a peptide itself, generated pRL1a-specific CTLs in the spleen cells of BALB/c mice. No enhancement of cytotoxicity was observed by emulsifying pRL1a MAP in incomplete Freund's adjuvant or in complete Freund's adjuvant for in vivo sensitization. Selective depletion of CD4+ T cells in mice by treatment with anti-L3T4 (CD4) monoclonal antibody and that of macrophages by treatment with carrageenan on in vivo sensitization with pRL1a MAP abrogated CTL generation. The findings suggest that CD4+ T cells and antigen-presenting cells were necessary for the in vivo priming of CD8+ T cells with pRL1a MAP. Furthermore, we demonstrated that in vivo sensitization of BALB/c mice with pRL1a MAP, but not with pRL1a peptide, showed an inhibitory effect on RL♂1 tumor growth. No growth-inhibitory effect was observed on control RVA, RVD, or Meth A tumors.

Original languageEnglish
Pages (from-to)1960-1964
Number of pages5
JournalCancer Research
Volume58
Issue number9
Publication statusPublished - May 1 1998

Fingerprint

Leukemia
Vaccination
Antigens
Peptides
T-Lymphocytes
Freund's Adjuvant
Carrageenan
Viral Tumor Antigens
Neoplasm Antigens
Antigen-Presenting Cells
Growth
Neoplasms
Spleen
Macrophages
Monoclonal Antibodies
Radiation
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Manki, A., Ono, T., Uenaka, A., Seino, Y., & Nakayama, E. (1998). Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia. Cancer Research, 58(9), 1960-1964.

Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia. / Manki, Akira; Ono, Toshiro; Uenaka, Akiko; Seino, Yoshiki; Nakayama, Eiichi.

In: Cancer Research, Vol. 58, No. 9, 01.05.1998, p. 1960-1964.

Research output: Contribution to journalArticle

Manki, A, Ono, T, Uenaka, A, Seino, Y & Nakayama, E 1998, 'Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia', Cancer Research, vol. 58, no. 9, pp. 1960-1964.
Manki A, Ono T, Uenaka A, Seino Y, Nakayama E. Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia. Cancer Research. 1998 May 1;58(9):1960-1964.
Manki, Akira ; Ono, Toshiro ; Uenaka, Akiko ; Seino, Yoshiki ; Nakayama, Eiichi. / Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia. In: Cancer Research. 1998 ; Vol. 58, No. 9. pp. 1960-1964.
@article{81d355532d744521abdb7264b147c0c9,
title = "Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia",
abstract = "pRL1a (IPGLPLSL) is the L(d)-binding tumor rejection antigen peptide recognized by CTLs on BALB/c radiation leukemia RL♂1. We demonstrated that in vivo and in vitro sensitization with pRL1a multiple antigen peptide (MAP), but not with the pRL1a peptide itself, generated pRL1a-specific CTLs in the spleen cells of BALB/c mice. No enhancement of cytotoxicity was observed by emulsifying pRL1a MAP in incomplete Freund's adjuvant or in complete Freund's adjuvant for in vivo sensitization. Selective depletion of CD4+ T cells in mice by treatment with anti-L3T4 (CD4) monoclonal antibody and that of macrophages by treatment with carrageenan on in vivo sensitization with pRL1a MAP abrogated CTL generation. The findings suggest that CD4+ T cells and antigen-presenting cells were necessary for the in vivo priming of CD8+ T cells with pRL1a MAP. Furthermore, we demonstrated that in vivo sensitization of BALB/c mice with pRL1a MAP, but not with pRL1a peptide, showed an inhibitory effect on RL♂1 tumor growth. No growth-inhibitory effect was observed on control RVA, RVD, or Meth A tumors.",
author = "Akira Manki and Toshiro Ono and Akiko Uenaka and Yoshiki Seino and Eiichi Nakayama",
year = "1998",
month = "5",
day = "1",
language = "English",
volume = "58",
pages = "1960--1964",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia

AU - Manki, Akira

AU - Ono, Toshiro

AU - Uenaka, Akiko

AU - Seino, Yoshiki

AU - Nakayama, Eiichi

PY - 1998/5/1

Y1 - 1998/5/1

N2 - pRL1a (IPGLPLSL) is the L(d)-binding tumor rejection antigen peptide recognized by CTLs on BALB/c radiation leukemia RL♂1. We demonstrated that in vivo and in vitro sensitization with pRL1a multiple antigen peptide (MAP), but not with the pRL1a peptide itself, generated pRL1a-specific CTLs in the spleen cells of BALB/c mice. No enhancement of cytotoxicity was observed by emulsifying pRL1a MAP in incomplete Freund's adjuvant or in complete Freund's adjuvant for in vivo sensitization. Selective depletion of CD4+ T cells in mice by treatment with anti-L3T4 (CD4) monoclonal antibody and that of macrophages by treatment with carrageenan on in vivo sensitization with pRL1a MAP abrogated CTL generation. The findings suggest that CD4+ T cells and antigen-presenting cells were necessary for the in vivo priming of CD8+ T cells with pRL1a MAP. Furthermore, we demonstrated that in vivo sensitization of BALB/c mice with pRL1a MAP, but not with pRL1a peptide, showed an inhibitory effect on RL♂1 tumor growth. No growth-inhibitory effect was observed on control RVA, RVD, or Meth A tumors.

AB - pRL1a (IPGLPLSL) is the L(d)-binding tumor rejection antigen peptide recognized by CTLs on BALB/c radiation leukemia RL♂1. We demonstrated that in vivo and in vitro sensitization with pRL1a multiple antigen peptide (MAP), but not with the pRL1a peptide itself, generated pRL1a-specific CTLs in the spleen cells of BALB/c mice. No enhancement of cytotoxicity was observed by emulsifying pRL1a MAP in incomplete Freund's adjuvant or in complete Freund's adjuvant for in vivo sensitization. Selective depletion of CD4+ T cells in mice by treatment with anti-L3T4 (CD4) monoclonal antibody and that of macrophages by treatment with carrageenan on in vivo sensitization with pRL1a MAP abrogated CTL generation. The findings suggest that CD4+ T cells and antigen-presenting cells were necessary for the in vivo priming of CD8+ T cells with pRL1a MAP. Furthermore, we demonstrated that in vivo sensitization of BALB/c mice with pRL1a MAP, but not with pRL1a peptide, showed an inhibitory effect on RL♂1 tumor growth. No growth-inhibitory effect was observed on control RVA, RVD, or Meth A tumors.

UR - http://www.scopus.com/inward/record.url?scp=0032080639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032080639&partnerID=8YFLogxK

M3 - Article

C2 - 9581839

AN - SCOPUS:0032080639

VL - 58

SP - 1960

EP - 1964

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 9

ER -